Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Mesoblast Limited (MESO) Price & Performance

AMZY trades at $11.35, down 2.32% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF has paid consistent weekly dividends, with recent distributions ranging from $0.06 to $0.14 per share. Key resistance and support levels are clustered around $12 and $11, respectively, indicating a tight trading range.

Outlook is cautious due to concerns over NAV erosion from its synthetic option strategy, as highlighted by Seeking Alpha. While high yields attract income seekers, the strategy may cap upside and amplify downside risk. Investors should weigh the income benefits against potential long-term underperformance relative to Amazon.

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.